The COVID-19 Vaccine Power from the US Centers for Disease Control and Prevention (CDC) stated that it has observed increased cases of myocarditis in young and young adults, especially between the ages of 12 and 24, after inoculation with authorized mRNA-based COVID 19 vaccines from Modern MRNA and Pfizer PFE /BioNTech BNTX.
Hundreds of cases of myocarditis and pericarditis, both conditions of inflammation of the heart, were reported to the US Government’s Vaccine (Vaccine Adverse Event Reporting System) after dose 1 of any mRNA-based vaccine in the last two months. Note that VAERS is a national early warning system to detect possible safety concerns in US licensed vaccines. The number of cases increased further after the second dose of these vaccines. In addition, cases occurred in a greater number of younger patients after dose 2 compared to dose 1
According to a Reuters report, the Israeli Ministry of Health raised the alarm when it reported a probable link of heart inflammation in young men who were vaccinated with Pfizer’s BNT162b earlier this month. Following this report, the CDC and health regulators in other countries began investigating such cases.
Although the number of reported cases is small compared to total vaccination with mRNA vaccines, they were higher than expected in the younger age groups.
We note that the CDC does not yet associate these side effects with mRNA vaccines and has scheduled a meeting of the Advisory Committee on Immunization Practice (ACIP) on June 18 to discuss and evaluate reports of myocarditis. In addition, the government authority has recommended the continuation of vaccination for anyone aged 12 years or older given the risk of COVID-19 disease and related complications.
However, we note that the CDC report also stated that more than 50% of myocardial infarction cases were reported in the age group 12-24, receiving only 8.8% of vaccine doses. This suggests that any negative outcome of the ACIP meeting scheduled for next week could hamper vaccination with mRNA vaccines in the young patient population and harm the prospects of these vaccine developers. However, the percentage of cases of inflammation suggests that the risks of these vaccines are significantly lower than their benefits. A CDC study claims that these vaccines are 91% effective. In addition, most patients facing inflammatory problems quickly felt better after medication and rest.
mRNA vaccine updates
We remind investors that Pfizer / BioNTech’s COVID-19 vaccine received approval for emergency use in teens last month from the FDA. Moderna applied for a similar permit in the United States, Europe and Canada earlier this month.
Meanwhile, Pfizer and BioNTech have promised two billion doses of their COVID-19 vaccines to ensure equal access to their vaccines globally. As part of the promise, the company plans to deliver 200 million doses in 2021 and 300 million doses in the first half of 2022 to the U.S. government at a non-profit price. The government will donate these doses to low- and lower-income countries and organizations that support them.
While Moderna and Pfizer have a Zacks Rank # 3 (Hold), BioNTech has a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks # 1 ranks stocks here.
+ 1,500% growth: One of 2021’s most exciting investment opportunities
In addition to the stocks you read about above, will you see Zacks’ best choice for capitalization on the Internet of Things (IoT)? It is one of the fastest growing technologies in history with an estimated 77 billion units to be connected by 2025. It accounts for 127 new units per second.
Zacks has released a special report to help you take advantage of the exponential growth of the Internet of Things. It reveals 4 sub-radar stocks that may be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report for FREE >>
Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Pfizer Inc. (PFE): Report on free stock analysis
Modern, Inc. (MRNA): Free stock analysis report
BioNTech SE sponsored ADR (BNTX): Free inventory analysis report
Click here to read this article on Zacks.com.